ClinicalTrials.gg
CompletedNCT05329194PASSAGEUpdated Jul 16, 2026Results posted

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

A Phase 4 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 37 sites in United States. Open to participants aged 12 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
286
Allocation
Not applicable
Ages
12 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
10th of 28
286 · median 121
Started
2022
with 3 others
Phase 4
2 of 28
1 open now
Registered
17th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 10th largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 4, and was the 17th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

Read the detailed description

This is a multicenter, single-arm, open-label, Post-authorization, Phase 4 study to assess the effectiveness of tezepelumab in the United States (US) among a real-world population of adults and adolescent participants with asthma requiring medium-dose to high-dose inhaled corticosteroids (ICS), with additional controller(s) for at least 12 months with documented history of at least 2 asthma exacerbations during the year prior to enrolment. The total duration of the study for each participant will be approximately 56 weeks. Approximately 400 participants will be enrolled. Participants will receive tezepelumab via subcutaneous injection at the study site, over a 48-week treatment period. The study also includes a post-dosing follow-up period from Weeks 48 to 52.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Inhaled corticosteroids (ICS)
  • Post-Authorization
  • Baseline Blood eosinophil count (BEC)
  • long-acting- β2 Agonist (LABA)
  • Real-world participant population
04

Who can participate

Ages eligible
12 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant must be 12 years of age or older, at the time of signing the form or assent.
  • Documented physician-diagnosed asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
  • Documented treatment with medium- to high dose ICS as per Global Initiative for Asthma (GINA) guidelines (GINA 2021) for at least 12 months prior to enrollment.
  • Use of additional asthma maintenance controller medication(s) in addition to ICS for at least 12 months prior to enrollment. The additional maintenance controller medication may be contained in a combination product (eg, ICS/ long-acting β-agonist (LABA)).
  • Documented history of at least 2 asthma exacerbations during the 12 months prior to enrollment.
  • Physician decision that participant is eligible for treatment with tezepelumab according to the approved United States product insert (USPI).
  • Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists).
  • Provision of signed and dated written informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Any to tezepelumab as per the US approved product label or in the opinion of the Investigator.
  • Comorbid diagnosis of severe or very severe (COPD) per GOLD guidelines (GOLD 2021).
  • Use of biologics that are approved for the treatment of asthma within 4 months or 5 half- lives (whichever is longer) prior to enrollment.
  • Participation in an interventional clinical trial for asthma within 12 months prior to enrollment.
  • Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.

    Drug: Tezepelumab

Interventions

  • Participants will be receiving subcutaneous injection of tezepelumab.

    Also known as: AMG 157 or MEDI9929

06

What researchers measure

Primary outcomes

  1. Annualized Asthma Exacerbation Rate (AAER)

    Asthma exacerbations were defined by worsening of asthma symptoms that leads to temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days, or an emergency department (ED) or urgent care visit due to asthma that required systemic corticosteroid (SCS), and/or inpatient hospitalization (≥24 hours) due to asthma. The AAER was based on exacerbations reported by the investigator over 52 weeks. The exacerbation rate was compared between the 12-month period before \[baseline period (BP)\] and the 12-month period after initiation of tezepelumab \[up to study Week 52 (Visit 15) = study period (SP)\].

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

Secondary outcomes

  1. Number of Participants With Asthma Exacerbations

    The number of participants with at least one asthma exacerbation in the 12-month period before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  2. Number of Participants Who Completed the 52 -Week Study Period With Any Reduction in Total Number of Asthma Exacerbations

    The number of participants who completed the 52 -week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed.

    Time frame: From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)

  3. Cumulative Asthma Exacerbation Days

    The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  4. Time to First Asthma Exacerbation

    The time to first exacerbation after initiation of tezepelumab was assessed. Data for median time to event have been presented for this endpoint. The median is the descriptive statistics median calculated using a subset of Participants with an event.

    Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)

  5. Rate of Asthma Exacerbations Associated With Hospitalizations

    The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  6. Rate of Asthma Exacerbations Associated With Emergency Department /Urgent Care (ED/UC) Visits

    The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  7. Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits

    The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  8. Number of Participants With Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits

    The number of participants with asthma exacerbations associated with hospitalizations or ED/UC visits in in the 12-month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  9. Cumulative Asthma Exacerbation Days Associated With Hospitalizations or ED/UC Visits

    The cumulative asthma exacerbation days associated with hospitalizations or ED/UC over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) were assessed. Total days of exacerbations resulting in hospitalizations or ED/UC visits have been presented.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  10. Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)

    Lung function (FEV1) was measured pre-bronchodilator (pre-BD) by spirometry test. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  11. Change From Baseline in Pre-bronchodilator FEV1

    Change from baseline in pre-bronchodilator FEV1 was assessed after initiation of tezepelumab. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)

  12. Number of Pre-BD FEV1 Responders

    Number of pre-BD FEV1 responders was defined as participants who achieved either at least 5% or 100 mL improvement from baseline.

    Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  13. Asthma Control Questionnaire (ACQ-6)

    The Asthma Control Questionnaire-6 (ACQ-6) is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control. The mean (average) ACQ-6 score is the mean of the responses.

    Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  14. Asthma Impairment and Risk Questionnaire (AIRQ)

    The Asthma Impairment and Risk Questionnaire (AIRQ) is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.

    Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  15. St. George's Respiratory Questionnaire (SGRQ)

    St. George's Respiratory Questionnaire (SGRQ) is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.

    Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  16. Change From Baseline in ACQ-6 Score

    Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score was assessed. The ACQ-6 is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control.

    Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)

  17. Change From Baseline in AIRQ Score

    Change from baseline in Asthma Impairment and Risk Questionnaire (AIRQ) score was assessed. AIRQ is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.

    Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)

  18. Change From Baseline in SGRQ Score

    Change from baseline in St. George's Respiratory Questionnaire (SGRQ) score was assessed. SGRQ is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.

    Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)

  19. Number of ACQ-6 Responders

    Number of ACQ-6 responders were assessed. Individual changes from baseline of ≥ 0.5 were considered to be clinically meaningful (minimum clinically important difference \[MCID\]). ACQ-6 responders in this study were defined as participants who achieved ≥ 1 MCID.

    Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  20. Number of AIRQ Responders

    Number of AIRQ responders were assessed. Individual changes from baseline of ≥ 2 were considered to be clinically meaningful (MCID). AIRQ responders in this study were defined as participants who achieved ≥ 1 MCID.

    Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  21. Number of SGRQ Responders

    Number of SGRQ responders were assessed. Individual changes from baseline of ≥ 4 were considered to be clinically meaningful (MCID). SGRQ (total and component score) responders in this study were defined as participants who achieved ≥ 1 MCID.

    Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)

  22. Number of Participants Who Require Any Systemic Corticosteroid (SCS) Use

    Number of participants who require any SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  23. Cumulative Annualized SCS Dose

    Cumulative annualized SCS dose in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed. Cumulative annualized SCS dose for each participant was calculated as followed: Cumulative annualized SCS dose = \[sum of (cumulative SCS dose)/length of the planned treatment period\]\*365.25

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  24. Number of Participants Who Require Longer-term (>30 Consecutive Days) SCS Use

    Number of participants who require longer-term (\>30 consecutive days) SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  25. Number and Type of Asthma-related Healthcare Resource Utilization (HRU)

    Number of participants with specific type of asthma-related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  26. Duration of Asthma-related Hospitalizations

    Duration of asthma-related hospitalization in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) was assessed.

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  27. AAER for Asthma Exacerbations (Subgroups of Participants)

    AAER based on asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: Blood eosinophil count (BEC) ≥300 cells/microliter; BEC \<300 cells/microliter; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate chronic obstructive pulmonary disease (COPD); Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  28. Number of Participants With Asthma Exacerbations (Subgroups of Participants)

    The number of participants with at least one asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  29. Number of Participants Who Completed the 52-week Study With Any Reduction in Total Number of Asthma Exacerbations (Subgroups of Participants)

    The number of participants who completed the 52-week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)

  30. Cumulative Asthma Exacerbation Days (Subgroups of Participants)

    The cumulative asthma exacerbation days over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  31. Rate of Asthma Exacerbations Associated With Hospitalizations (Subgroups of Participants)

    Rate of asthma exacerbations associated with hospitalization over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in the following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  32. Rate of Asthma Exacerbations Associated With Emergency Department/Urgent Care (ED/UC) Visits (Subgroups of Participants)

    Rate of asthma exacerbations associated with ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  33. Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits (Subgroups of Participants)

    Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  34. Number and Type of Asthma-related HRU (Subgroups of Participants)

    Number of participants with specific type of asthma related HRU in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking). FEIA = Fluorescent enzyme immunoassay

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

  35. Duration of Asthma-related Hospitalizations (Subgroups of Participants)

    Duration of asthma-related hospitalization in 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: BEC≥300 cells/µL; BEC\<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

    Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

Other outcomes

  1. Number of Participants With Serious Adverse Events (SAEs), Adverse Events That Lead to Tezepelumab Treatment Discontinuation (DAEs), and Adverse Events of Special Interest (AESIs)

    The safety and tolerability of tezepelumab were assessed. Data for adverse events on-treatment period have been presented.

    Time frame: Up to Week 52

07

Results

Posted Jul 16, 2026

Participant flow

The study was conducted from 29 April 2022 (first participant first visit) to 01 October 2025 (last participant last visit) at 32 study sites in the United States of America (USA).

Participant flow — Overall Study
MilestoneTezepelumab
Started286
Completed255
Not completed31
Withdrew: Death2
Withdrew: Development of study-specific withdrawal criteria2
Withdrew: Lost to follow-up6
Withdrew: Other5
Withdrew: Withdrawal by subject16

Outcome measures

PrimaryAnnualized Asthma Exacerbation Rate (AAER)

Asthma exacerbations were defined by worsening of asthma symptoms that leads to temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days, or an emergency department (ED) or urgent care visit due to asthma that required systemic corticosteroid (SCS), and/or inpatient hospitalization (≥24 hours) due to asthma. The AAER was based on exacerbations reported by the investigator over 52 weeks. The exacerbation rate was compared between the 12-month period before \[baseline period (BP)\] and the 12-month period after initiation of tezepelumab \[up to study Week 52 (Visit 15) = study period (SP)\].

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Adjusted rate (exacerbations per year)
Annualized Asthma Exacerbation Rate (AAER)
Adjusted rate (exacerbations per year)Tezepelumab
Baseline Period2.8783 ± 2.69
Study Period0.8665 ± 0.71
SecondaryNumber of Participants With Asthma Exacerbations

The number of participants with at least one asthma exacerbation in the 12-month period before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Asthma Exacerbations
ParticipantsTezepelumab
Baseline Period285
Study Period120
SecondaryNumber of Participants Who Completed the 52 -Week Study Period With Any Reduction in Total Number of Asthma Exacerbations

The number of participants who completed the 52 -week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed.

Time frame:
From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Completed the 52 -Week Study Period With Any Reduction in Total Number of Asthma Exacerbations
ParticipantsTezepelumab
At least 50% reduction209
100% reduction148
SecondaryCumulative Asthma Exacerbation Days

The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Days
Cumulative Asthma Exacerbation Days
DaysTezepelumab
Baseline Period8855
Study Period2326
SecondaryTime to First Asthma Exacerbation

The time to first exacerbation after initiation of tezepelumab was assessed. Data for median time to event have been presented for this endpoint. The median is the descriptive statistics median calculated using a subset of Participants with an event.

Time frame:
Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Reported as:
Median · Days
Time to First Asthma Exacerbation
DaysTezepelumab
Visit861 (NA to NA)
Visit15102 (NA to NA)
SecondaryRate of Asthma Exacerbations Associated With Hospitalizations

The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Adjusted rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Hospitalizations
Adjusted rate (exacerbations per year)Tezepelumab
Study Period0.0364 ± 0.02
Baseline Period0.1714 ± 0.12
SecondaryRate of Asthma Exacerbations Associated With Emergency Department /Urgent Care (ED/UC) Visits

The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Adjusted rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Emergency Department /Urgent Care (ED/UC) Visits
Adjusted rate (exacerbations per year)Tezepelumab
Study Period0.1568 ± 0.11
Baseline Period0.6771 ± 0.55
SecondaryRate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits

The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Adjusted rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits
Adjusted rate (exacerbations per year)Tezepelumab
Study Period0.1647 ± 0.11
Baseline Period0.6807 ± 0.55
SecondaryNumber of Participants With Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits

The number of participants with asthma exacerbations associated with hospitalizations or ED/UC visits in in the 12-month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits
ParticipantsTezepelumab
Baseline Period102
Study Period34
SecondaryCumulative Asthma Exacerbation Days Associated With Hospitalizations or ED/UC Visits

The cumulative asthma exacerbation days associated with hospitalizations or ED/UC over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) were assessed. Total days of exacerbations resulting in hospitalizations or ED/UC visits have been presented.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Days
Cumulative Asthma Exacerbation Days Associated With Hospitalizations or ED/UC Visits
DaysTezepelumab
Baseline Period2518
Study Period517
SecondaryPre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)

Lung function (FEV1) was measured pre-bronchodilator (pre-BD) by spirometry test. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

Time frame:
Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Litre (L)
Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)
Litre (L)Tezepelumab
Baseline2.160 ± 0.735
Visit 82.257 ± 0.776
Visit 152.281 ± 0.743
SecondaryChange From Baseline in Pre-bronchodilator FEV1

Change from baseline in pre-bronchodilator FEV1 was assessed after initiation of tezepelumab. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

Time frame:
Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Litre (L)
Change From Baseline in Pre-bronchodilator FEV1
Litre (L)Tezepelumab
Change from baseline: Visit 80.113 ± 0.361
Change from baseline: Visit 150.111 ± 0.403
SecondaryNumber of Pre-BD FEV1 Responders

Number of pre-BD FEV1 responders was defined as participants who achieved either at least 5% or 100 mL improvement from baseline.

Time frame:
Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Count of participants · Participants
Number of Pre-BD FEV1 Responders
ParticipantsTezepelumab
Visit8128
Visit15107
SecondaryAsthma Control Questionnaire (ACQ-6)

The Asthma Control Questionnaire-6 (ACQ-6) is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control. The mean (average) ACQ-6 score is the mean of the responses.

Time frame:
Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
Asthma Control Questionnaire (ACQ-6)
Scores on a scaleTezepelumab
Baseline2.3863 ± 1.1588
Visit81.2971 ± 1.0078
Visit151.1291 ± 1.0164
SecondaryAsthma Impairment and Risk Questionnaire (AIRQ)

The Asthma Impairment and Risk Questionnaire (AIRQ) is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.

Time frame:
Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
Asthma Impairment and Risk Questionnaire (AIRQ)
Scores on a scaleTezepelumab
Baseline5.1 ± 2.5
Visit82.3 ± 2.4
Visit152.2 ± 2.5
SecondarySt. George's Respiratory Questionnaire (SGRQ)

St. George's Respiratory Questionnaire (SGRQ) is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.

Time frame:
Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
St. George's Respiratory Questionnaire (SGRQ)
Scores on a scaleTezepelumab
Baseline52.4219 ± 19.9071
Visit831.7205 ± 21.3066
Visit1529.9202 ± 22.6859
SecondaryChange From Baseline in ACQ-6 Score

Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score was assessed. The ACQ-6 is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control.

Time frame:
Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
Change From Baseline in ACQ-6 Score
Scores on a scaleTezepelumab
Visit8-1.0944 ± 1.1486
Visit15-1.2352 ± 1.2540
SecondaryChange From Baseline in AIRQ Score

Change from baseline in Asthma Impairment and Risk Questionnaire (AIRQ) score was assessed. AIRQ is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.

Time frame:
Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
Change From Baseline in AIRQ Score
Scores on a scaleTezepelumab
Visit8-2.9 ± 2.7
Visit15-2.9 ± 2.8
SecondaryChange From Baseline in SGRQ Score

Change from baseline in St. George's Respiratory Questionnaire (SGRQ) score was assessed. SGRQ is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.

Time frame:
Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Reported as:
Mean · Scores on a scale
Change From Baseline in SGRQ Score
Scores on a scaleTezepelumab
Visit8-20.9296 ± 19.9668
Visit15-22.2776 ± 22.1774
SecondaryNumber of ACQ-6 Responders

Number of ACQ-6 responders were assessed. Individual changes from baseline of ≥ 0.5 were considered to be clinically meaningful (minimum clinically important difference \[MCID\]). ACQ-6 responders in this study were defined as participants who achieved ≥ 1 MCID.

Time frame:
Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Count of participants · Participants
Number of ACQ-6 Responders
ParticipantsTezepelumab
Visit8180
Visit15162
SecondaryNumber of AIRQ Responders

Number of AIRQ responders were assessed. Individual changes from baseline of ≥ 2 were considered to be clinically meaningful (MCID). AIRQ responders in this study were defined as participants who achieved ≥ 1 MCID.

Time frame:
Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Count of participants · Participants
Number of AIRQ Responders
ParticipantsTezepelumab
Visit8168
Visit15139
SecondaryNumber of SGRQ Responders

Number of SGRQ responders were assessed. Individual changes from baseline of ≥ 4 were considered to be clinically meaningful (MCID). SGRQ (total and component score) responders in this study were defined as participants who achieved ≥ 1 MCID.

Time frame:
Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Reported as:
Count of participants · Participants
Number of SGRQ Responders
ParticipantsTezepelumab
Visit8207
Visit15175
SecondaryNumber of Participants Who Require Any Systemic Corticosteroid (SCS) Use

Number of participants who require any SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Require Any Systemic Corticosteroid (SCS) Use
ParticipantsTezepelumab
Baseline Period279
Study Period129
SecondaryCumulative Annualized SCS Dose

Cumulative annualized SCS dose in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed. Cumulative annualized SCS dose for each participant was calculated as followed: Cumulative annualized SCS dose = \[sum of (cumulative SCS dose)/length of the planned treatment period\]\*365.25

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Mean · mg/year
Cumulative Annualized SCS Dose
mg/yearTezepelumab
Baseline Period3671.704 ± 24494.741
Study Period1283.780 ± 3983.790
SecondaryNumber of Participants Who Require Longer-term (>30 Consecutive Days) SCS Use

Number of participants who require longer-term (\>30 consecutive days) SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Require Longer-term (>30 Consecutive Days) SCS Use
ParticipantsTezepelumab
Baseline Period22
Study Period11
SecondaryNumber and Type of Asthma-related Healthcare Resource Utilization (HRU)

Number of participants with specific type of asthma-related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number and Type of Asthma-related Healthcare Resource Utilization (HRU)
ParticipantsTezepelumab
Any health-related events Baseline Period211
Any health-related events Study Period166
Asthma health-related events Baseline Period211
Asthma health-related events Study Period166
Ambulance transport Baseline Period6
Ambulance transport Study Period4
Hospitalization intensive care Baseline Period11
Hospitalization intensive care Study Period2
Hospitalization coronary care Baseline Period2
Hospitalization coronary care Study Period3
Hospitalization general care Baseline Period24
Hospitalization general care Study Period22
Urgent care visit Baseline Period63
Urgent care visit Study Period46
Emergency room visit Baseline Period59
Emergency room visit Study Period54
Hospital admission or emergency department >24 hours Baseline Period35
Hospital admission or emergency department >24 hours Study Period28
Visit to specialist Baseline Period188
Visit to specialist Study Period138
Visit to primary health care physician Baseline Period98
Visit to primary health care physician Study Period71
Other health care visit Baseline Period22
Other health care visit Study Period38
Home visit physician Baseline Period0
Home visit physician Study Period0
Home visit nurse Baseline Period2
Home visit nurse Study Period2
Home visit other health care Baseline Period0
Home visit other health care Study Period3
Telephone call physician Baseline Period34
Telephone call physician Study Period41
Telephone call nurse Baseline Period26
Telephone call nurse Study Period25
Telephone call specialist Baseline Period66
Telephone call specialist Study Period64
Telephone call other physician/health care Baseline Period11
Telephone call other physician/health care Study Period26
Medical testing spirometry Baseline Period124
Medical testing spirometry Study Period75
Medical testing advanced pulmonary function test Baseline Period35
Medical testing advanced pulmonary function test Study Period12
Medical testing plain chest X-ray Baseline Period80
Medical testing plain chest X-ray Study Period57
Medical testing computed tomography Baseline Period48
Medical testing computed tomography Study Period39
Medical testing oxygen initiated Baseline Period20
Medical testing oxygen initiated Study Period10
SecondaryDuration of Asthma-related Hospitalizations

Duration of asthma-related hospitalization in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) was assessed.

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Crude rate (days per year)
Duration of Asthma-related Hospitalizations
Crude rate (days per year)Tezepelumab
Hospitalization Study Period5.7382
Hospitalization Baseline Period4.3374
Hospitalization intensive care Study Period3.4928
Hospitalization intensive care Baseline Period4.9259
Hospitalization general care Study Period6.0572
Hospitalization general care Baseline Period3.2612
SecondaryAAER for Asthma Exacerbations (Subgroups of Participants)

AAER based on asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: Blood eosinophil count (BEC) ≥300 cells/microliter; BEC \<300 cells/microliter; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate chronic obstructive pulmonary disease (COPD); Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Adjusted rate (exacerbations per year)
AAER for Asthma Exacerbations (Subgroups of Participants)
Adjusted rate (exacerbations per year)Tezepelumab
Baseline BEC: <300 Study Period0.9751 (0.76 to 1.25)
Baseline BEC: <300 Baseline Period2.8092 (2.61 to 3.02)
Baseline BEC: ≥300 Study Period0.7142 (0.53 to 0.96)
Baseline BEC: ≥300 Baseline Period2.9865 (2.63 to 3.40)
All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period1.0585 (0.80 to 1.40)
All perennial FEIA negative Baseline Period2.8411 (2.57 to 3.14)
Any perennial FEIA positive Study Period0.7352 (0.57 to 0.95)
Any perennial FEIA positive Baseline Period2.8939 (2.64 to 3.17)
Baseline BEC <300 & with all perennial FEIA negative Study Period1.2936 (0.92 to 1.81)
Baseline BEC <300 & with all perennial FEIA negative Baseline Period2.8269 (2.51 to 3.18)
Baseline BEC <300 & with any perennial FEIA positive Study Period0.7345 (0.51 to 1.06)
Baseline BEC <300 & with any perennial FEIA positive Baseline Period2.8020 (2.55 to 3.08)
Baseline BEC ≥300 & with all perennial FEIA negative Study Period0.7032 (0.45 to 1.10)
Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period2.8677 (2.41 to 3.41)
Baseline BEC ≥300 & with any perennial FEIA positive Study Period0.7175 (0.49 to 1.06)
Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period3.0649 (2.56 to 3.67)
Black or African American Study Period0.9007 (0.61 to 1.34)
Black or African American Baseline Period3.2865 (2.81 to 3.85)
Adolescents Study Period0.6684 (0.34 to 1.30)
Adolescents Baseline Period2.3218 (1.97 to 2.74)
Mild to moderate COPD Study Period0.9377 (0.60 to 1.46)
Mild to moderate COPD Baseline Period2.7046 (2.42 to 3.03)
Baseline smoking status Study Period1.0363 (0.74 to 1.46)
Baseline smoking status Baseline Period2.8811 (2.63 to 3.16)
SecondaryNumber of Participants With Asthma Exacerbations (Subgroups of Participants)

The number of participants with at least one asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Asthma Exacerbations (Subgroups of Participants)
ParticipantsTezepelumab
Allergic & BEC ≥300 Baseline Period75
Allergic & BEC ≥300 Study Period30
Non-allergic & BEC ≥300 Baseline Period45
Non-allergic & BEC ≥300 Study Period19
Allergic & BEC <300 Baseline Period89
Allergic & BEC <300 Study Period32
Non-allergic & BEC <300 Baseline Period74
Non-allergic & BEC <300 Study Period37
Black/African American Baseline Period63
Black/African American Study Period27
Adolescents Baseline Period19
Adolescents Study Period7
Mild to moderate COPD Baseline Period57
Mild to moderate COPD Study Period26
Smokers Baseline Period83
Smokers Study Period38
SecondaryNumber of Participants Who Completed the 52-week Study With Any Reduction in Total Number of Asthma Exacerbations (Subgroups of Participants)

The number of participants who completed the 52-week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Completed the 52-week Study With Any Reduction in Total Number of Asthma Exacerbations (Subgroups of Participants)
ParticipantsTezepelumab
Allergic and BEC ≥300 ≥50% reduction60
Allergic and BEC ≥300 100% reduction40
Non-allergic and BEC ≥300 ≥50% reduction36
Non-allergic and BEC ≥300 100% reduction26
Allergic and BEC <300 ≥50% reduction68
Allergic and BEC <300 100% reduction50
Non-allergic and BEC <300 ≥50% reduction44
Non-allergic and BEC <300 100% reduction32
Black/African American ≥50% reduction44
Black/African American 100% reduction31
Adolescents ≥50% reduction14
Adolescents 100% reduction10
Mild to moderate COPD ≥50% reduction41
Mild to moderate COPD 100% reduction28
Smokers ≥50% reduction56
Smokers 100% reduction39
SecondaryCumulative Asthma Exacerbation Days (Subgroups of Participants)

The cumulative asthma exacerbation days over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Days
Cumulative Asthma Exacerbation Days (Subgroups of Participants)
DaysTezepelumab
Allergic and BEC ≥300 Baseline Period2539
Allergic and BEC ≥300 Study Period478
Non-allergic and BEC ≥300 Baseline Period1230
Non-allergic and BEC ≥300 Study Period291
Allergic and BEC <300 Baseline Period2735
Allergic and BEC <300 Study Period727
Non-allergic and BEC <300 Baseline Period2322
Non-allergic and BEC <300 Study Period806
Black/African American Baseline Period1865
Black/African American Study Period441
Adolescents Baseline Period425
Adolescents Study Period73
Mild to moderate COPD Baseline Period1679
Mild to moderate COPD Study Period554
Smokers Baseline Period2384
Smokers Study Period837
SecondaryRate of Asthma Exacerbations Associated With Hospitalizations (Subgroups of Participants)

Rate of asthma exacerbations associated with hospitalization over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in the following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Crude rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Hospitalizations (Subgroups of Participants)
Crude rate (exacerbations per year)Tezepelumab
Baseline BEC: <300 Study Period0.0663
Baseline BEC: <300 Baseline Period0.1925
Baseline BEC: ≥300 Study Period0.0000
Baseline BEC: ≥300 Baseline Period0.1420
All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period0.0626
All perennial FEIA negative Baseline Period0.1269
Any perennial FEIA positive Study Period0.0188
Any perennial FEIA positive Baseline Period0.2006
Baseline BEC <300 & with all perennial FEIA negative Study Period0.1032
Baseline BEC <300 & with all perennial FEIA negative Baseline Period0.1361
Baseline BEC <300 & with any perennial FEIA positive Study Period0.0361
Baseline BEC <300 & with any perennial FEIA positive Baseline Period0.2399
Baseline BEC ≥300 & with all perennial FEIA negative Study Period0.0000
Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period0.1118
Baseline BEC ≥300 & with any perennial FEIA positive Study Period0.0000
Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period0.1600
Black or African American Study Period0.0343
Black or African American Baseline Period0.4083
Adolescents Study Period0.0000
Adolescents Baseline Period0.2685
Mild to moderate COPD Study Period0.0555
Mild to moderate COPD Baseline Period0.1958
Baseline smokers Study Period0.0387
Baseline smokers Baseline Period0.2195
SecondaryRate of Asthma Exacerbations Associated With Emergency Department/Urgent Care (ED/UC) Visits (Subgroups of Participants)

Rate of asthma exacerbations associated with ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Crude rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Emergency Department/Urgent Care (ED/UC) Visits (Subgroups of Participants)
Crude rate (exacerbations per year)Tezepelumab
Baseline BEC: <300 Study Period0.2205
Baseline BEC: <300 Baseline Period0.6567
Baseline BEC: ≥300 Study Period0.0679
Baseline BEC: ≥300 Baseline Period0.6340
All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period0.1800
All perennial FEIA negative Baseline Period0.5706
Any perennial FEIA positive Study Period0.1390
Any perennial FEIA positive Baseline Period0.7007
Baseline BEC <300 & with all perennial FEIA negative Study Period0.2224
Baseline BEC <300 & with all perennial FEIA negative Baseline Period0.5997
Baseline BEC <300 & with any perennial FEIA positive Study Period0.2189
Baseline BEC <300 & with any perennial FEIA positive Baseline Period0.7046
Baseline BEC ≥300 & with all perennial FEIA negative Study Period0.1144
Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period0.5230
Baseline BEC ≥300 & with any perennial FEIA positive Study Period0.0405
Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period0.7012
Black or African American Study Period0.2595
Black or African American Baseline Period1.0795
Adolescents Study Period0.0000
Adolescents Baseline Period0.4866
Mild to moderate COPD Study Period0.2049
Mild to moderate COPD Baseline Period0.5630
Baseline smokers Study Period0.1688
Baseline smokers Baseline Period0.6520
SecondaryRate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits (Subgroups of Participants)

Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Crude rate (exacerbations per year)
Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits (Subgroups of Participants)
Crude rate (exacerbations per year)Tezepelumab
Baseline BEC: <300 Study Period0.2339
Baseline BEC: <300 Baseline Period0.6632
Baseline BEC: ≥300 Study Period0.0679
Baseline BEC: ≥300 Baseline Period0.6340
All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period0.1981
All perennial FEIA negative Baseline Period0.5794
Any perennial FEIA positive Study Period0.1390
Any perennial FEIA positive Baseline Period0.7007
Baseline BEC <300 & with all perennial FEIA negative Study Period0.2524
Baseline BEC <300 & with all perennial FEIA negative Baseline Period0.6140
Baseline BEC <300 & with any perennial FEIA positive Study Period0.2189
Baseline BEC <300 & with any perennial FEIA positive Baseline Period0.7046
Baseline BEC ≥300 & with all perennial FEIA negative Study Period0.1144
Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period0.5230
Baseline BEC ≥300 & with any perennial FEIA positive Study Period0.0405
Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period0.7012
Black or African American Study Period0.2595
Black or African American Baseline Period1.0795
Adolescents Study Period0.0000
Adolescents Baseline Period0.4866
Mild to moderate COPD Study Period0.2236
Mild to moderate COPD Baseline Period0.5630
Baseline smokers Study Period0.1819
Baseline smokers Baseline Period0.6520
SecondaryNumber and Type of Asthma-related HRU (Subgroups of Participants)

Number of participants with specific type of asthma related HRU in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking). FEIA = Fluorescent enzyme immunoassay

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Count of participants · Participants
Number and Type of Asthma-related HRU (Subgroups of Participants)
ParticipantsTezepelumab
Baseline BEC<300 Any health-related events Baseline Period121
Baseline BEC<300 Any health-related events Study Period99
Baseline BEC<300 Asthma health-related events Baseline Period121
Baseline BEC<300 Asthma health-related events Study Period99
Baseline BEC<300 Ambulance transport Baseline Period2
Baseline BEC<300 Ambulance transport Study Period4
Baseline BEC<300 Hospitalization intensive care Baseline Period7
Baseline BEC<300 Hospitalization intensive care Study Period1
Baseline BEC<300 Hospitalization coronary care Baseline Period1
Baseline BEC<300 Hospitalization coronary care Study Period1
Baseline BEC<300 Hospitalization general care Baseline Period14
Baseline BEC<300 Hospitalization general care Study Period19
Baseline BEC<300 Urgent care visit Baseline Period30
Baseline BEC<300 Urgent care visit Study Period29
Baseline BEC<300 Emergency room visit Baseline Period33
Baseline BEC<300 Emergency room visit Study Period39
Baseline BEC<300 Hospital admission or emergency department >24 hours Baseline Period22
Baseline BEC<300 Hospital admission or emergency department >24 hours Study Period23
Baseline BEC<300 Visit to specialist Baseline Period109
Baseline BEC<300 Visit to specialist Study Period81
Baseline BEC<300 Visit to primary health care physician Baseline Period54
Baseline BEC<300 Visit to primary health care physician Study Period42
Baseline BEC<300 Other health care visit Baseline Period13
Baseline BEC<300 Other health care visit Study Period27
Baseline BEC<300 Home visit physician Baseline Period0
Baseline BEC<300 Home visit physician Study Period0
Baseline BEC<300 Home visit nurse Baseline Period0
Baseline BEC<300 Home visit nurse Study Period1
Baseline BEC<300 Home visit other health care Baseline Period0
Baseline BEC<300 Home visit other health care Study Period2
Baseline BEC<300 Telephone call physician Baseline Period20
Baseline BEC<300 Telephone call physician Study Period26
Baseline BEC<300 Telephone call nurse Baseline Period14
Baseline BEC<300 Telephone call nurse Study Period15
Baseline BEC<300 Telephone call specialist Baseline Period35
Baseline BEC<300 Telephone call specialist Study Period37
Baseline BEC<300 Telephone call other physician/health care Baseline Period6
Baseline BEC<300 Telephone call other physician/health care Study Period16
Baseline BEC<300 Medical testing spirometry Baseline Period66
Baseline BEC<300 Medical testing spirometry Study Period43
Baseline BEC<300 Medical testing advanced pulmonary function test Baseline Period17
Baseline BEC<300 Medical testing advanced pulmonary function test Study Period9
Baseline BEC<300 Medical testing plain chest X-ray Baseline Period48
Baseline BEC<300 Medical testing plain chest X-ray Study Period42
Baseline BEC<300 Medical testing computed tomography Baseline Period29
Baseline BEC<300 Medical testing computed tomography Study Period32
Baseline BEC<300 Medical testing oxygen initiated Baseline Period14
Baseline BEC<300 Medical testing oxygen initiated Study Period7
Baseline BEC≥300 Any health-related events Baseline Period89
Baseline BEC≥300 Any health-related events Study Period65
Baseline BEC≥300 Asthma health-related events Baseline Period89
Baseline BEC≥300 Asthma health-related events Study Period65
Baseline BEC≥300 Ambulance transport Baseline Period4
Baseline BEC≥300 Ambulance transport Study Period0
Baseline BEC≥300 Hospitalization intensive care Baseline Period4
Baseline BEC≥300 Hospitalization intensive care Study Period1
Baseline BEC≥300 Hospitalization coronary care Baseline Period1
Baseline BEC≥300 Hospitalization coronary care Study Period2
Baseline BEC≥300 Hospitalization general care Baseline Period10
Baseline BEC≥300 Hospitalization general care Study Period3
Baseline BEC≥300 Urgent care visit Baseline Period32
Baseline BEC≥300 Urgent care visit Study Period16
Baseline BEC≥300 Emergency room visit Baseline Period26
Baseline BEC≥300 Emergency room visit Study Period15
Baseline BEC≥300 Hospital admission or emergency department >24 hours Baseline Period13
Baseline BEC≥300 Hospital admission or emergency department >24 hours Study Period5
Baseline BEC≥300 Visit to specialist Baseline Period78
Baseline BEC≥300 Visit to specialist Study Period55
Baseline BEC≥300 Visit to primary health care physician Baseline Period44
Baseline BEC≥300 Visit to primary health care physician Study Period28
Baseline BEC≥300 Other health care visit Baseline Period9
Baseline BEC≥300 Other health care visit Study Period11
Baseline BEC≥300 Home visit physician Baseline Period0
Baseline BEC≥300 Home visit physician Study Period0
Baseline BEC≥300 Home visit nurse Baseline Period2
Baseline BEC≥300 Home visit nurse Study Period1
Baseline BEC≥300 Home visit other health care Baseline Period0
Baseline BEC≥300 Home visit other health care Study Period1
Baseline BEC≥300 Telephone call physician Baseline Period14
Baseline BEC≥300 Telephone call physician Study Period14
Baseline BEC≥300 Telephone call nurse Baseline Period12
Baseline BEC≥300 Telephone call nurse Study Period10
Baseline BEC≥300 Telephone call specialist Baseline Period31
Baseline BEC≥300 Telephone call specialist Study Period25
Baseline BEC≥300 Telephone call other physician/health care Baseline Period5
Baseline BEC≥300 Telephone call other physician/health care Study Period10
Baseline BEC≥300 Medical testing spirometry Baseline Period58
Baseline BEC≥300 Medical testing spirometry Study Period31
Baseline BEC≥300 Medical testing advanced pulmonary function test Baseline Period18
Baseline BEC≥300 Medical testing advanced pulmonary function test Study Period3
Baseline BEC≥300 Medical testing plain chest X-ray Baseline Period31
Baseline BEC≥300 Medical testing plain chest X-ray Study Period14
Baseline BEC≥300 Medical testing computed tomography Baseline Period18
Baseline BEC≥300 Medical testing computed tomography Study Period7
Baseline BEC≥300 Medical testing oxygen initiated Baseline Period6
Baseline BEC≥300 Medical testing oxygen initiated Study Period3
All perennial FEIA negative Any health-related events Baseline Period88
All perennial FEIA negative Any health-related events Study Period73
All perennial FEIA negative Asthma health-related events Baseline Period88
All perennial FEIA negative Asthma health-related events Study Period73
All perennial FEIA negative Ambulance transport Baseline Period1
All perennial FEIA negative Ambulance transport Study Period1
All perennial FEIA negative Hospitalization intensive care Baseline Period2
All perennial FEIA negative Hospitalization intensive care Study Period0
All perennial FEIA negative Hospitalization coronary care Baseline Period0
All perennial FEIA negative Hospitalization coronary care Study Period0
All perennial FEIA negative Hospitalization general care Baseline Period8
All perennial FEIA negative Hospitalization general care Study Period11
All perennial FEIA negative Urgent care visit Baseline Period25
All perennial FEIA negative Urgent care visit Study Period25
All perennial FEIA negative Emergency room visit Baseline Period20
All perennial FEIA negative Emergency room visit Study Period24
All perennial FEIA negative Hospital admission or emergency department >24 hours Baseline Period11
All perennial FEIA negative Hospital admission or emergency department >24 hours Study Period13
All perennial FEIA negative Visit to specialist Baseline Period77
All perennial FEIA negative Visit to specialist Study Period57
All perennial FEIA negative Visit to primary health care physician Baseline Period35
All perennial FEIA negative Visit to primary health care physician Study Period36
All perennial FEIA negative Other health care visit Baseline Period8
All perennial FEIA negative Other health care visit Study Period16
All perennial FEIA negative Home visit physician Baseline Period0
All perennial FEIA negative Home visit physician Study Period0
All perennial FEIA negative Home visit nurse Baseline Period0
All perennial FEIA negative Home visit nurse Study Period2
All perennial FEIA negative Home visit other health care Baseline Period0
All perennial FEIA negative Home visit other health care Study Period2
All perennial FEIA negative Telephone call physician Baseline Period15
All perennial FEIA negative Telephone call physician Study Period20
All perennial FEIA negative Telephone call nurse Baseline Period10
All perennial FEIA negative Telephone call nurse Study Period14
All perennial FEIA negative Telephone call specialist Baseline Period26
All perennial FEIA negative Telephone call specialist Study Period25
All perennial FEIA negative Telephone call other physician/health care Baseline Period3
All perennial FEIA negative Telephone call other physician/health care Study Period14
All perennial FEIA negative Medical testing spirometry Baseline Period41
All perennial FEIA negative Medical testing spirometry Study Period27
All perennial FEIA negative Medical testing advanced pulmonary function test Baseline Period13
All perennial FEIA negative Medical testing advanced pulmonary function test Study Period7
All perennial FEIA negative Medical testing plain chest X-ray Baseline Period28
All perennial FEIA negative Medical testing plain chest X-ray Study Period28
All perennial FEIA negative Medical testing computed tomography Baseline Period26
All perennial FEIA negative Medical testing computed tomography Study Period24
All perennial FEIA negative Medical testing oxygen initiated Baseline Period4
All perennial FEIA negative Medical testing oxygen initiated Study Period2
Any perennial FEIA positive Any health-related events Baseline Period123
Any perennial FEIA positive Any health-related events Study Period93
Any perennial FEIA positive Asthma health-related events Baseline Period123
Any perennial FEIA positive Asthma health-related events Study Period93
Any perennial FEIA positive Ambulance transport Baseline Period5
Any perennial FEIA positive Ambulance transport Study Period3
Any perennial FEIA positive Hospitalization intensive care Baseline Period9
Any perennial FEIA positive Hospitalization intensive care Study Period2
Any perennial FEIA positive Hospitalization coronary care Baseline Period2
Any perennial FEIA positive Hospitalization coronary care Study Period3
Any perennial FEIA positive Hospitalization general care Baseline Period16
Any perennial FEIA positive Hospitalization general care Study Period11
Any perennial FEIA positive Urgent care visit Baseline Period38
Any perennial FEIA positive Urgent care visit Study Period21
Any perennial FEIA positive Emergency room visit Baseline Period39
Any perennial FEIA positive Emergency room visit Study Period30
Any perennial FEIA positive Hospital admission or emergency department >24 hours Baseline Period24
Any perennial FEIA positive Hospital admission or emergency department >24 hours Study Period15
Any perennial FEIA positive Visit to specialist Baseline Period111
Any perennial FEIA positive Visit to specialist Study Period81
Any perennial FEIA positive Visit to primary health care physician Baseline Period63
Any perennial FEIA positive Visit to primary health care physician Study Period35
Any perennial FEIA positive Other health care visit Baseline Period14
Any perennial FEIA positive Other health care visit Study Period22
Any perennial FEIA positive Home visit physician Baseline Period0
Any perennial FEIA positive Home visit physician Study Period0
Any perennial FEIA positive Home visit nurse Baseline Period2
Any perennial FEIA positive Home visit nurse Study Period0
Any perennial FEIA positive Home visit other health care Baseline Period0
Any perennial FEIA positive Home visit other health care Study Period1
Any perennial FEIA positive Telephone call physician Baseline Period19
Any perennial FEIA positive Telephone call physician Study Period21
Any perennial FEIA positive Telephone call nurse Baseline Period16
Any perennial FEIA positive Telephone call nurse Study Period11
Any perennial FEIA positive Telephone call specialist Baseline Period40
Any perennial FEIA positive Telephone call specialist Study Period39
Any perennial FEIA positive Telephone call other physician/health care Baseline Period8
Any perennial FEIA positive Telephone call other physician/health care Study Period12
Any perennial FEIA positive Medical testing spirometry Baseline Period83
Any perennial FEIA positive Medical testing spirometry Study Period48
Any perennial FEIA positive Medical testing advanced pulmonary function test Baseline Period22
Any perennial FEIA positive Medical testing advanced pulmonary function test Study Period5
Any perennial FEIA positive Medical testing plain chest X-ray Baseline Period52
Any perennial FEIA positive Medical testing plain chest X-ray Study Period29
Any perennial FEIA positive Medical testing computed tomography Baseline Period22
Any perennial FEIA positive Medical testing computed tomography Study Period15
Any perennial FEIA positive Medical testing oxygen initiated Baseline Period16
Any perennial FEIA positive Medical testing oxygen initiated Study Period8
Black/African American Any health-related events Baseline Period47
Black/African American Any health-related events Study Period40
Black/African American Asthma health-related events Baseline Period47
Black/African American Asthma health-related events Study Period40
Black/African American Ambulance transport Baseline Period4
Black/African American Ambulance transport Study Period3
Black/African American Hospitalization intensive care Baseline Period4
Black/African American Hospitalization intensive care Study Period0
Black/African American Hospitalization coronary care Baseline Period1
Black/African American Hospitalization coronary care Study Period2
Black/African American Hospitalization general care Baseline Period16
Black/African American Hospitalization general care Study Period8
Black/African American Urgent care visit Baseline Period15
Black/African American Urgent care visit Study Period11
Black/African American Emergency room visit Baseline Period28
Black/African American Emergency room visit Study Period16
Black/African American Hospital admission or emergency department >24 hours Baseline Period18
Black/African American Hospital admission or emergency department >24 hours Study Period10
Black/African American Visit to specialist Baseline Period42
Black/African American Visit to specialist Study Period34
Black/African American Visit to primary health care physician Baseline Period25
Black/African American Visit to primary health care physician Study Period17
Black/African American Other health care visit Baseline Period8
Black/African American Other health care visit Study Period9
Black/African American Home visit physician Baseline Period0
Black/African American Home visit physician Study Period0
Black/African American Home visit nurse Baseline Period2
Black/African American Home visit nurse Study Period0
Black/African American Home visit other health care Baseline Period0
Black/African American Home visit other health care Study Period1
Black/African American Telephone call physician Baseline Period10
Black/African American Telephone call physician Study Period13
Black/African American Telephone call nurse Baseline Period9
Black/African American Telephone call nurse Study Period4
Black/African American Telephone call specialist Baseline Period17
Black/African American Telephone call specialist Study Period12
Black/African America Telephone call other physician/health care Baseline Period5
Black/African American Telephone call other physician/health care Study Period7
Black/African American Medical testing spirometry Baseline Period34
Black/African American Medical testing spirometry Study Period24
Black/African American Medical testing advanced pulmonary function test Baseline Period12
Black/African American Medical testing advanced pulmonary function test Study Period2
Black/African American Medical testing plain chest X-ray Baseline Period28
Black/African American Medical testing plain chest X-ray Study Period16
Black/African American Medical testing computed tomography Baseline Period9
Black/African American Medical testing computed tomography Study Period7
Black/African American Medical testing oxygen initiated Baseline Period9
Black/African American Medical testing oxygen initiated Study Period3
Adolescents Any health-related events Baseline Period12
Adolescents Any health-related events Study Period7
Adolescents Asthma health-related events Baseline Period12
Adolescents Asthma health-related events Study Period7
Adolescents Ambulance transport Baseline Period0
Adolescents Ambulance transport Study Period0
Adolescents Hospitalization intensive care Baseline Period2
Adolescents Hospitalization intensive care Study Period1
Adolescents Hospitalization coronary care Baseline Period0
Adolescents Hospitalization coronary care Study Period0
Adolescents Hospitalization general care Baseline Period1
Adolescents Hospitalization general care Study Period1
Adolescents Urgent care visit Baseline Period3
Adolescents Urgent care visit Study Period1
Adolescents Emergency room visit Baseline Period4
Adolescents Emergency room visit Study Period1
Adolescents Hospital admission or emergency department >24 hours Baseline Period3
Adolescents Hospital admission or emergency department >24 hours Study Period1
Adolescents Visit to specialist Baseline Period9
Adolescents Visit to specialist Study Period6
Adolescents Visit to primary health care physician Baseline Period7
Adolescents Visit to primary health care physician Study Period1
Adolescents Other health care visit Baseline Period0
Adolescents Other health care visit Study Period0
Adolescents Home visit physician Baseline Period0
Adolescents Home visit physician Study Period0
Adolescents Home visit nurse Baseline Period0
Adolescents Home visit nurse Study Period0
Adolescents Home visit other health care Baseline Period0
Adolescents Home visit other health care Study Period0
Adolescents Telephone call physician Baseline Period0
Adolescents Telephone call physician Study Period2
Adolescents Telephone call nurse Baseline Period1
Adolescents Telephone call nurse Study Period0
Adolescents Telephone call specialist Baseline Period1
Adolescents Telephone call specialist Study Period4
Adolescents Telephone call other physician/health care Baseline Period0
Adolescents Telephone call other physician/health care Study Period0
Adolescents Medical testing spirometry Baseline Period10
Adolescents Medical testing spirometry Study Period2
Adolescents Medical testing advanced pulmonary function test Baseline Period3
Adolescents Medical testing advanced pulmonary function test Study Period1
Adolescents Medical testing plain chest X-ray Baseline Period2
Adolescents Medical testing plain chest X-ray Study Period1
Adolescents Medical testing computed tomography Baseline Period0
Adolescents Medical testing computed tomography Study Period0
Adolescents Medical testing oxygen initiated Baseline Period2
Adolescents Medical testing oxygen initiated Study Period1
Mild to moderate COPD Any health-related events Baseline Period42
Mild to moderate COPD Any health-related events Study Period35
Mild to moderate COPD Asthma health-related events Baseline Period42
Mild to moderate COPD Asthma health-related events Study Period35
Mild to moderate COPD Ambulance transport Baseline Period1
Mild to moderate COPD Ambulance transport Study Period2
Mild to moderate COPD Hospitalization intensive care Baseline Period2
Mild to moderate COPD Hospitalization intensive care Study Period0
Mild to moderate COPD Hospitalization coronary care Baseline Period2
Mild to moderate COPD Hospitalization coronary care Study Period2
Mild to moderate COPD Hospitalization general care Baseline Period6
Mild to moderate COPD Hospitalization general care Study Period8
Mild to moderate COPD Urgent care visit Baseline Period15
Mild to moderate COPD Urgent care visit Study Period11
Mild to moderate COPD Emergency room visit Baseline Period12
Mild to moderate COPD Emergency room visit Study Period15
Mild to moderate COPD Hospital admission or emergency department >24 hours Baseline Period6
Mild to moderate COPD Hospital admission or emergency department >24 hours Study Period10
Mild to moderate COPD Visit to specialist Baseline Period36
Mild to moderate COPD Visit to specialist Study Period31
Mild to moderate COPD Visit to primary health care physician Baseline Period17
Mild to moderate COPD Visit to primary health care physician Study Period18
Mild to moderate COPD Other health care visit Baseline Period9
Mild to moderate COPD Other health care visit Study Period12
Mild to moderate COPD Home visit physician Baseline Period0
Mild to moderate COPD Home visit physician Study Period0
Mild to moderate COPD Home visit nurse Baseline Period0
Mild to moderate COPD Home visit nurse Study Period1
Mild to moderate COPD Home visit other health care Baseline Period0
Mild to moderate COPD Home visit other health care Study Period2
Mild to moderate COPD Telephone call physician Baseline Period8
Mild to moderate COPD Telephone call physician Study Period10
Mild to moderate COPD Telephone call nurse Baseline Period2
Mild to moderate COPD Telephone call nurse Study Period6
Mild to moderate COPD Telephone call specialist Baseline Period8
Mild to moderate COPD Telephone call specialist Study Period12
Mild to moderate COPD Telephone call other physician/health care Baseline Period2
Mild to moderate COPD Telephone call other physician/health care Study Period9
Mild to moderate COPD Medical testing spirometry Baseline Period21
Mild to moderate COPD Medical testing spirometry Study Period17
Mild to moderate COPD Medical testing advanced pulmonary function test Baseline Period7
Mild to moderate COPD Medical testing advanced pulmonary function test Study Period2
Mild to moderate COPD Medical testing plain chest X-ray Baseline Period17
Mild to moderate COPD Medical testing plain chest X-ray Study Period22
Mild to moderate COPD Medical testing computed tomography Baseline Period13
Mild to moderate COPD Medical testing computed tomography Study Period13
Mild to moderate COPD Medical testing oxygen initiated Baseline Period7
Mild to moderate COPD Medical testing oxygen initiated Study Period5
Baseline Smokers Any health-related events Baseline Period58
Baseline Smokers Any health-related events Study Period51
Baseline Smokers Asthma health-related events Baseline Period58
Baseline Smokers Asthma health-related events Study Period51
Baseline Smokers Ambulance transport Baseline Period0
Baseline Smokers Ambulance transport Study Period2
Baseline Smokers Hospitalization intensive care Baseline Period5
Baseline Smokers Hospitalization intensive care Study Period0
Baseline Smokers Hospitalization coronary care Baseline Period2
Baseline Smokers Hospitalization coronary care Study Period2
Baseline Smokers Hospitalization general care Baseline Period7
Baseline Smokers Hospitalization general care Study Period7
Baseline Smokers Urgent care visit Baseline Period24
Baseline Smokers Urgent care visit Study Period17
Baseline Smokers Emergency room visit Baseline Period16
Baseline Smokers Emergency room visit Study Period21
Baseline Smokers Hospital admission or emergency department >24 hours Baseline Period9
Baseline Smokers Hospital admission or emergency department >24 hours Study Period10
Baseline Smokers Visit to specialist Baseline Period49
Baseline Smokers Visit to specialist Study Period44
Baseline Smokers Visit to primary health care physician Baseline Period24
Baseline Smokers Visit to primary health care physician Study Period24
Baseline Smokers Other health care visit Baseline Period7
Baseline Smokers Other health care visit Study Period14
Baseline Smokers Home visit physician Baseline Period0
Baseline Smokers Home visit physician Study Period0
Baseline Smokers Home visit nurse Baseline Period0
Baseline Smokers Home visit nurse Study Period1
Baseline Smokers Home visit other health care Baseline Period0
Baseline Smokers Home visit other health care Study Period2
Baseline Smokers Telephone call physician Baseline Period13
Baseline Smokers Telephone call physician Study Period17
Baseline Smokers Telephone call nurse Baseline Period9
Baseline Smokers Telephone call nurse Study Period9
Baseline Smokers Telephone call specialist Baseline Period19
Baseline Smokers Telephone call specialist Study Period21
Baseline Smokers Telephone call other physician/health care Baseline Period2
Baseline Smokers Telephone call other physician/health care Study Period9
Baseline Smokers Medical testing spirometry Baseline Period26
Baseline Smokers Medical testing spirometry Study Period24
Baseline Smokers Medical testing advanced pulmonary function test Baseline Period6
Baseline Smokers Medical testing advanced pulmonary function test Study Period2
Baseline Smokers Medical testing plain chest X-ray Baseline Period25
Baseline Smokers Medical testing plain chest X-ray Study Period27
Baseline Smokers Medical testing computed tomography Baseline Period18
Baseline Smokers Medical testing computed tomography Study Period19
Baseline Smokers Medical testing oxygen initiated Baseline Period6
Baseline Smokers Medical testing oxygen initiated Study Period4
SecondaryDuration of Asthma-related Hospitalizations (Subgroups of Participants)

Duration of asthma-related hospitalization in 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: BEC≥300 cells/µL; BEC\<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).

Time frame:
Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Reported as:
Number · Crude Rate (days per year)
Duration of Asthma-related Hospitalizations (Subgroups of Participants)
Crude Rate (days per year)Tezepelumab
Baseline BEC: <300, hospitalization Study Period6.5463
Baseline BEC: <300, hospitalization Baseline Period4.9057
Baseline BEC: <300, hospitalization general care Study Period6.6300
Baseline BEC: <300, hospitalization general care Baseline Period3.2970
Baseline BEC ≥300, hospitalization Study Period2.7070
Baseline BEC ≥300, hospitalization Baseline Period3.5506
Baseline BEC ≥300, hospitalization general care Study Period2.6136
Baseline BEC ≥300, hospitalization general care Baseline Period3.2110
All perennial fluorescent enzyme immunoassay (FEIA) negative, hospitalization Study Period5.6316
All perennial FEIA negative, hospitalization Baseline Period2.7594
All perennial FEIA negative, hospitalization general care Study Period5.6316
All perennial FEIA negative, hospitalization general care Baseline Period2.1323
Any perennial FEIA positive, hospitalization Study Period5.8273
Any perennial FEIA positive, hospitalization Baseline Period4.8863
Any perennial FEIA positive, hospitalization intensive care Study Period3.4928
Any perennial FEIA positive, hospitalization intensive care Baseline Period5.4631
Any perennial FEIA positive, hospitalization general care Study Period6.5206
Any perennial FEIA positive, hospitalization general care Baseline Period3.8256
Baseline BEC <300 & with all perennial FEIA negative, hospitalization Study Period5.9877
Baseline BEC <300 & with all perennial FEIA negative, hospitalization Baseline Period3.2110
Baseline BEC <300 & with all perennial FEIA negative, hospitalization general care Study Period5.9877
Baseline BEC <300 & with all perennial FEIA negative, hospitalization general care Baseline Period2.4082
Baseline BEC ≥300 & with any perennial FEIA positive, hospitalization Study Period2.8760
Baseline BEC ≥300 & with any perennial FEIA positive, hospitalization Baseline Period4.0137
Black/African American, hospitalization Study Period5.5664
Black/African American, hospitalization Baseline Period3.6006
Black/African American, hospitalization general care Study Period5.9368
Black/African American, hospitalization general care Baseline Period2.8849
Mild to moderate COPD, hospitalization Study Period6.6060
Mild to moderate COPD, hospitalization Baseline Period6.7373
Mild to moderate COPD, hospitalization general care Study Period7.3133
Mild to moderate COPD, hospitalization general care Baseline Period4.1810
Baseline smokers, hospitalization Study Period9.2988
Baseline smokers, hospitalization Baseline Period3.4117
Baseline smokers, hospitalization general care Study Period10.5870
Baseline smokers, hospitalization general care Baseline Period1.5768
Baseline BEC <300 & with any perennial FEIA positive, hospitalization Study Period7.1639
Baseline BEC <300 & with any perennial FEIA positive, hospitalization Baseline Period5.5575
Baseline BEC <300 & with any perennial FEIA positive, hospitalization general care Study Period7.4268
Baseline BEC <300 & with any perennial FEIA positive, hospitalization general care Baseline Period3.7908
Other pre-specifiedNumber of Participants With Serious Adverse Events (SAEs), Adverse Events That Lead to Tezepelumab Treatment Discontinuation (DAEs), and Adverse Events of Special Interest (AESIs)

The safety and tolerability of tezepelumab were assessed. Data for adverse events on-treatment period have been presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs), Adverse Events That Lead to Tezepelumab Treatment Discontinuation (DAEs), and Adverse Events of Special Interest (AESIs)
ParticipantsTezepelumab
Any SAE28
Any SAE with outcome of death1
Any AE leading to study intervention discontinuation6

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab2/286 (0.7%)31/286 (10.8%)4/286 (1.4%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventTezepelumab
AsthmaRespiratory, thoracic and mediastinal disorders6/286
PneumoniaInfections and infestations4/286
Pneumonia bacterialInfections and infestations3/286
Non-cardiac chest painGeneral disorders2/286
Atypical pneumoniaInfections and infestations1/286
COVID-19Infections and infestations1/286
COVID-19 pneumoniaInfections and infestations1/286
Pneumonia viralInfections and infestations1/286
Postoperative wound infectionInfections and infestations1/286
Respiratory syncytial virus infectionInfections and infestations1/286
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTezepelumab
NeuralgiaNervous system disorders1/286
SyncopeNervous system disorders1/286
NauseaGastrointestinal disorders1/286
AlopeciaSkin and subcutaneous tissue disorders1/286
Rash erythematousSkin and subcutaneous tissue disorders1/286
Ligament sprainInjury, poisoning and procedural complications1/286
Procedural painInjury, poisoning and procedural complications1/286
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders1/286
Muscle spasmsMusculoskeletal and connective tissue disorders1/286
Muscle twitchingMusculoskeletal and connective tissue disorders1/286

Baseline characteristics

Full analysis set (FAS) included all enrolled subjects who received at least 1 dose of tezepelumab, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(years)Tezepelumab
Mean52.9 ± 16.2
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab
Female186
Male100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tezepelumab
Hispanic or Latino27
Not Hispanic or Latino259
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab
White204
Black or African American63
Asian8
American Indian or Alaska Native4
Multiple0
Not reported2
Other5
08

Study locations

37 sites
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Long Beach, California 90815, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Rancho Mirage, California 92270, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Washington D.C., District of Columbia 20037, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Lexington, Kentucky 40509, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Upper Marlboro, Maryland 20772, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Saint Paul, Minnesota 55109, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Lincoln, Nebraska 68505, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Hollis, New York 11423, United States
  • Research Site
    Horseheads, New York 14845, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Valhalla, New York 10595, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Warwick, Rhode Island 02886, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Hendersonville, Tennessee 37075, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Charlottesville, Virginia 22903, United States
  • Research Site
    Vancouver, Washington 98664, United States
09

References and documents

Publications

  • Lugogo NL, Akuthota P, Sumino K, Burnette AF, Mathur SK, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B. Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study. Am J Respir Crit Care Med. 2026 May 18:aamag225. doi: 10.1093/ajrccm/aamag225. Online ahead of print. PubMed 42148905 ↗
  • Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B. Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study. Adv Ther. 2025 Jul;42(7):3334-3353. doi: 10.1007/s12325-025-03231-6. Epub 2025 May 19. PubMed 40388086 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Oct 2025, 41 months.

Results were first posted in Jul 2026, 9 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 41 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Apr 14, 2022
StartActual
Apr 29, 2022
Primary completionActual
Oct 1, 2025
CompletionActual
Oct 1, 2025
Results first posted
Jul 16, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05329194
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Apr 29, 2022
Primary completion
Oct 1, 2025
Completion
Oct 1, 2025
Results posted
Jul 16, 2026
Last update
Jul 16, 2026

Study contacts

Njira Lugogo., MD.
principal investigator · University of Michigan Health. Michigan, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion